The HFSA Heart Failure Seminar: Focus on HFSA Scientific Statement on Cardio-Oncology and Heart Failure – A Focus on Key Takeaways. This dynamic, case-based virtual seminar will explore the Cardio-Oncology and Heart Failure Scientific Statement from the Heart Failure Society of America. Hear directly from the statement's authors as they discuss four complex case presentations, followed by insightful panel discussions. 

Following this activity, participants will be better able to:

1. Recognize the lack of uniform guidelines and the need for standardized cardiac monitoring in cancer therapies beyond anthracyclines and trastuzumab.
2. Explain the evolving concept of permissive cardiotoxicity and how it may allow continued cancer treatment while managing cardiac risk in high-risk patients.
3. Identify urgent treatment steps for ICI-associated myocarditis and explore therapies beyond corticosteroids.
4. Discuss heart transplant eligibility in cancer patients, emphasizing a personalized approach.

The Heart Failure Society of America (HFSA) is committed to ensuring balance, independence, objectivity, and scientific rigor in its educational activities. HFSA has a disclosure policy that requires oral presenters to disclose all relevant financial relationships for themselves and their spouse or partner during the past 24-months with any commercial entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients and related to the content of the activity, whether or not these commercial entities are supporters of the activity.

Speakers will have a disclosure slide at the beginning of each presentation. All potential conflicts of interests have been resolved in accordance with the ACCME Updated Standards for Commercial Support.

The following faculty and/or accreditors with ability to control content for this activity have no conflict of interest: 

• Michelle Bloom, MD -- Advisory Panel: AstraZeneca (Ended); Consultant: AstraZeneca (Ended); Speaker's Bureau (Ended)
• Ana Barac, MD, PhD -- Advisor: AstraZeneca (Ended)
• Anju Nohria, MD, MSc - Research Support: Bristol Myers Squibb; Consultant: AstraZeneca; DSMB Member - Takeda Oncology
• Alana Ferrari, PharmD, BCOP -- Consultant: Janssen Pharmaceuticals, Inc.
• Nicolas Palaskas, MD -- Consultant: Kiniksa Pharmaceuticals

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.

In support of improving patient care, The Heart Failure Society of America is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for PHarmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Heart Failure Society of America designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This educational activity is approved for nursing continuing professional development (NCPD) units by the Heart Failure Society of America.  This activity is approved for a maximum of 1.50 contact hours.

The Heart Failure Society of America is an accredited provider of continuing pharmacy education (CPE). This event is accredited for up to 1.50 contact hours of knowledge-based CPE.  ACPE Universal Activity Numbers (UAN): JA4008267-0000-25-003-L01-P (on-site/live attendance only); JA4008267-0000-25-004-H01-P (on-demand/home study)

The Heart Failure Society of America has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.50 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.